AIMS: The prevalence of highly insulin-resistant diabetes is increasing and treatment requires the use of very high doses of insulin. This study was performed to analyze efficacy and patient satisfaction with use of U-500 concentrated insulin. METHODS: The medical records of 40 patients using U-500 insulin for at least 3 months were reviewed. A quality of life questionnaire was administered 6 or more months after U-500 was initiated. Effects of U-500 use on HbA1c, weight, total daily insulin use, hypoglycemia, and patient satisfaction were measured. RESULTS: Patients had uncontrolled diabetes for 3 years prior to U-500 initiation despite insulin titration. Subjects required continued insulin titration to attain glycemic control even after U-500 initiation, but HbA1c decreased by 1.5% within 3 months. Subjects gained weight with insulin titration. Hypoglycemic symptoms increased early after transition to U-500 insulin, but patients reported fewer hypoglycemic episodes on the quality of life questionnaire. Patient satisfaction with diabetes care and control was significantly improved following transition to U-500 insulin. CONCLUSIONS: Use of U-500 insulin assists with attaining glycemic control in highly insulin-resistant subjects, but at the cost of weight gain and increased insulin doses. However, patient satisfaction is improved with U-500 insulin use. Published by Elsevier Ireland Ltd.
AIMS: The prevalence of highly insulin-resistant diabetes is increasing and treatment requires the use of very high doses of insulin. This study was performed to analyze efficacy and patient satisfaction with use of U-500 concentrated insulin. METHODS: The medical records of 40 patients using U-500insulin for at least 3 months were reviewed. A quality of life questionnaire was administered 6 or more months after U-500 was initiated. Effects of U-500 use on HbA1c, weight, total daily insulin use, hypoglycemia, and patient satisfaction were measured. RESULTS:Patients had uncontrolled diabetes for 3 years prior to U-500 initiation despite insulin titration. Subjects required continued insulin titration to attain glycemic control even after U-500 initiation, but HbA1c decreased by 1.5% within 3 months. Subjects gained weight with insulin titration. Hypoglycemic symptoms increased early after transition to U-500insulin, but patients reported fewer hypoglycemic episodes on the quality of life questionnaire. Patient satisfaction with diabetes care and control was significantly improved following transition to U-500insulin. CONCLUSIONS: Use of U-500insulin assists with attaining glycemic control in highly insulin-resistant subjects, but at the cost of weight gain and increased insulin doses. However, patient satisfaction is improved with U-500insulin use. Published by Elsevier Ireland Ltd.
Authors: J A Galloway; C T Spradlin; R L Nelson; S M Wentworth; J A Davidson; J L Swarner Journal: Diabetes Care Date: 1981 May-Jun Impact factor: 19.112
Authors: Amparo de la Peña; Xiaosu Ma; Shobha Reddy; Fernando Ovalle; Richard M Bergenstal; Jeffrey A Jackson Journal: J Diabetes Sci Technol Date: 2014-05-12
Authors: Amparo de la Peña; Matthew Riddle; Linda A Morrow; Honghua H Jiang; Helle Linnebjerg; Adam Scott; Khin M Win; Marcus Hompesch; Kenneth F Mace; Jennie G Jacobson; Jeffrey A Jackson Journal: Diabetes Care Date: 2011-10-12 Impact factor: 19.112